DMK Pharmaceuticals Corporation stock is up 2.55% since 30 days ago. The next earnings date is Feb 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.83% of the previous 28 December’s closed higher than November. 100% of analysts rate it a buy.
Adamis Pharmaceuticals Corporation develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis.